Statin use was associated with a reduction in all-cause and multiple myeloma-specific mortality.
A retrospective analysis of data from the Veterans Administration (VA) Central Cancer Registry has identified an association between statin use and mortality in patients with multiple myeloma (MM). Specifically, statin therapy was associated with a reduced risk of all-cause and MM-specific mortality.
Of the nearly 5000 patients diagnosed with MM between 1999 and 2013, 2294 received statin therapy. Statin use was defined by the authors as the presence of any prescription of statin within 3 months before or after MM diagnosis in the patient. Patients had access to the following statins within the VA system:
Variability in dosing and potency were accounted for by calculating the daily defined dose, as is specified by the World Health Organization. The cohort was followed through October 2014; the median follow-up for statin users was 34 months and for nonstatin users, 26 months. Survival was measured from the date of MM diagnosis until the date of death, which was obtained from the VA vital status file.
Interestingly, statin use was associated with a 21% reduction in all-cause mortality (adjusted hazard ratio [HR], 0.79; 95% CI, 0.73-0.86; P <.001) and a 24% decrease in MM-specific mortality (adjusted HR, 0.76; 95% CI, 0.67-0.86; P <.001). Older age, body-mass index greater than 19.5 kg/m2, higher comorbidity score, hemoglobin less than 10 g/dL, and use of pamidronate were all associated with increased MM-specific mortality.
The authors point out, however, that misclassification of statin use within the VA registry was possible, a result of patient noncompliance. They conclude that while their results suggest an association between statin therapy and MM-specific as well as all-cause mortality in patients with MM, a prospective study would be ideal to corroborate these findings.
Reference
Sanfilippo KM, Keller J, Gage BF, et al. Statins are associated with reduced mortality in multiple myeloma. J Clin Oncol. 2016;34(33): 4008-4014. doi: 10.1200/JCO.2016.68.3482.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More